"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 4 | 6 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 8 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 7 | 3 | 10 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 2 | 6 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 3 | 7 |
| 2009 | 7 | 2 | 9 |
| 2010 | 13 | 5 | 18 |
| 2011 | 11 | 4 | 15 |
| 2012 | 9 | 3 | 12 |
| 2013 | 8 | 6 | 14 |
| 2014 | 9 | 3 | 12 |
| 2015 | 9 | 5 | 14 |
| 2016 | 9 | 9 | 18 |
| 2017 | 11 | 11 | 22 |
| 2018 | 6 | 10 | 16 |
| 2019 | 9 | 10 | 19 |
| 2020 | 10 | 9 | 19 |
| 2021 | 7 | 14 | 21 |
| 2022 | 1 | 18 | 19 |
| 2023 | 2 | 10 | 12 |
| 2024 | 15 | 13 | 28 |
| 2025 | 16 | 2 | 18 |
| 2026 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
AANA Journal Course-GLP-1 Receptor Agonists: What CRNAs Need to Know About Their Expanding Role. AANA J. 2026 Jun 01; 94(3):225-233.
-
Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes. J Manag Care Spec Pharm. 2026 Jun; 32(6):717-734.
-
Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Medicine (Baltimore). 2026 May 29; 105(22):e49050.
-
Geroprotective effects of diet and exercise plus metformin in frail older veterans with obesity: The DEMFOS randomized trial protocol. Contemp Clin Trials. 2026 Jun; 165:108321.
-
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. Endocr Pract. 2026 Apr; 32(4):473-518.
-
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026 Feb 01; 49(2):325-334.
-
Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026 Feb 01; 49(2):344-351.
-
Safety and Glycemic Outcomes Among Youth With New-Onset Type 1 Diabetes Using a Tubeless Automated Insulin Delivery System. J Diabetes Res. 2026; 2026(1):e2896084.
-
Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
-
Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation. Clin Transplant. 2025 Oct; 39(10):e70344.